152 related articles for article (PubMed ID: 36330525)
1. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM
Front Immunol; 2022; 13():1023023. PubMed ID: 36330525
[TBL] [Abstract][Full Text] [Related]
2. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
[TBL] [Abstract][Full Text] [Related]
3. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
4. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Jørgensen NG; Klausen U; Grauslund JH; Helleberg C; Aagaard TG; Do TH; Ahmad SM; Olsen LR; Klausen TW; Breinholt MF; Hansen M; Martinenaite E; Met Ö; Svane IM; Knudsen LM; Andersen MH
Front Immunol; 2020; 11():595035. PubMed ID: 33240282
[TBL] [Abstract][Full Text] [Related]
5. First in man study: Bcl-Xl_42-CAF
Mørk SK; Kongsted P; Westergaard MCW; Albieri B; Granhøj JS; Donia M; Martinenaite E; Holmström MO; Madsen K; Kverneland AH; Kjeldsen JW; Holmstroem RB; Lorentzen CL; Nørgaard N; Andreasen LV; Wood GK; Christensen D; Klausen MS; Hadrup SR; Thor Straten P; Andersen MH; Svane IM
Front Immunol; 2023; 14():1122977. PubMed ID: 36999039
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
7. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
13. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE; Lisle TL; Perez-Penco M; Schina A; Hübbe ML; Siersbæk M; Holmström MO; Jørgensen MA; Marie Svane I; Met Ö; Ødum N; Madsen DH; Donia M; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316062
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Kloor M; Prigge ES; Sauer M; Al-Batran SE; Kaufmann AM; Schneider A; Jäger E; von Knebel Doeberitz M
Cancer; 2016 May; 122(9):1425-33. PubMed ID: 26949913
[TBL] [Abstract][Full Text] [Related]
15. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
Rahma OE; Hamilton JM; Wojtowicz M; Dakheel O; Bernstein S; Liewehr DJ; Steinberg SM; Khleif SN
J Transl Med; 2014 Feb; 12():55. PubMed ID: 24565030
[TBL] [Abstract][Full Text] [Related]
16. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
[TBL] [Abstract][Full Text] [Related]
17. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
Aaboe Jørgensen M; Ugel S; Linder Hübbe M; Carretta M; Perez-Penco M; Weis-Banke SE; Martinenaite E; Kopp K; Chapellier M; Adamo A; De Sanctis F; Frusteri C; Iezzi M; Zocca MB; Hargbøll Madsen D; Wakatsuki Pedersen A; Bronte V; Andersen MH
Cancer Immunol Res; 2021 Nov; 9(11):1316-1326. PubMed ID: 34518197
[TBL] [Abstract][Full Text] [Related]
18. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
19. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.
Storkus WJ; Maurer D; Lin Y; Ding F; Bose A; Lowe D; Rose A; DeMark M; Karapetyan L; Taylor JL; Chelvanambi M; Fecek RJ; Filderman JN; Looney TJ; Miller L; Linch E; Lowman GM; Kalinski P; Butterfield LH; Tarhini A; Tawbi H; Kirkwood JM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
